FDA Probes Potential Cancer Risk in CAR-T Therapy

The FDA is investigating whether CAR-T therapy, a treatment that uses genetically modified white blood cells to attack tumors, can cause lymphoma, a blood cancer. While the overall benefits of CAR-T therapy still outweigh the potential risks, the agency is evaluating the need for regulatory action after reports of T cell lymphoma in patients who received the treatment. Experts in the field are surprised by the announcement, as they had not previously seen data about this risk.